Business Description
Tempest Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US87978U1088
Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.59 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.99 | |||||
Debt-to-EBITDA | -0.73 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.2 | |||||
3-Year EPS without NRI Growth Rate | 12.9 | |||||
3-Year FCF Growth Rate | 14.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.38 | |||||
9-Day RSI | 30.65 | |||||
14-Day RSI | 32.47 | |||||
6-1 Month Momentum % | -7.68 | |||||
12-1 Month Momentum % | 182.99 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.13 | |||||
Quick Ratio | 3.13 | |||||
Cash Ratio | 3.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.2 | |||||
Shareholder Yield % | -82.72 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -239.27 | |||||
ROA % | -79.13 | |||||
ROIC % | -171.56 | |||||
ROC (Joel Greenblatt) % | -250.04 | |||||
ROCE % | -97.97 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.19 | |||||
Price-to-Tangible-Book | 2.18 | |||||
EV-to-EBIT | -1.17 | |||||
EV-to-Forward-EBIT | -0.93 | |||||
EV-to-EBITDA | -1.19 | |||||
EV-to-Forward-EBITDA | -0.93 | |||||
EV-to-FCF | -1.25 | |||||
Price-to-Net-Current-Asset-Value | 4.57 | |||||
Price-to-Net-Cash | 5.2 | |||||
Earnings Yield (Greenblatt) % | -85.47 | |||||
FCF Yield % | -58.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tempest Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.591 | ||
Beta | 0 | ||
Volatility % | 1075.82 | ||
14-Day RSI | 32.47 | ||
14-Day ATR (€) | 0.310432 | ||
20-Day SMA (€) | 2.8096 | ||
12-1 Month Momentum % | 182.99 | ||
52-Week Range (€) | 0.212 - 8.6 | ||
Shares Outstanding (Mil) | 22.22 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Tempest Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Tempest Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Tempest Therapeutics Inc Frequently Asked Questions
What is Tempest Therapeutics Inc(STU:3OS)'s stock price today?
The current price of STU:3OS is €1.87. The 52 week high of STU:3OS is €8.60 and 52 week low is €0.21.
When is next earnings date of Tempest Therapeutics Inc(STU:3OS)?
The next earnings date of Tempest Therapeutics Inc(STU:3OS) is 2024-08-30 Est..
Does Tempest Therapeutics Inc(STU:3OS) pay dividends? If so, how much?
Tempest Therapeutics Inc(STU:3OS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |